satralizumab NMOSD
Selected indexed studies
- International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab. (Neurol Neuroimmunol Neuroinflamm, 2023) [PMID:37258412]
- Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar. (Mult Scler Relat Disord, 2022) [PMID:36007339]
- Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. (J Neurol, 2024) [PMID:37676297]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab. (2023) pubmed
- Satralizumab: First Approval. (2020) pubmed
- Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. (2019) pubmed
- Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. (2020) pubmed
- Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar. (2022) pubmed
- Long-term Efficacy of Satralizumab in AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar. (2023) pubmed
- Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. (2024) pubmed
- Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies. (2021) pubmed
- Advances in the long-term treatment of neuromyelitis optica spectrum disorder. (2024) pubmed
- Long-term safety of satralizumab in NMOSD. (2022) pubmed